Studies Presented at American Transplant Congress Describe Validation of RNA Sequencing for Post-Transplant Management of Kidney Graft Recipients

Studies by the scientific founders of Transplant Genomics Inc. (TGI) to be presented at the upcoming American Transplant Congress (ATC) May 2–6 in Philadelphia demonstrate validation of the company’s tests to support management of kidney transplant recipients. The tests are designed to detect early signs of kidney graft injury, differentiate between actionable causes and enable optimization of therapy, with the potential to extend lives and reduce costs of associated healthcare.

“These studies validate the use of our tests in both peripheral blood and biopsies to classify the immune status of kidney graft recipients,” explained Stan Rose, PhD, President & CEO of Transplant Genomics and a kidney transplant recipient himself. “The validation of the first blood-based signature for subclinical acute rejection is an important milestone in our efforts to offer noninvasive serial monitoring of immune status in kidney transplant recipients.”

Validation of Blood and Biopsy Gene Expression-Based Molecular Diagnostics for Subclinical Acute Rejection: Comparing DNA Microarrays Vs. Next-Generation RNA Sequencing will be presented on Sunday, May 3. In this study, Dr. Friedewald, Dr. Kurian and colleagues substantiate RNA sequencing as an alternative data generation platform for analyzing gene expression profiles in blood and tissue from kidney transplant recipients. The data validate that gene expression signatures for subclinical acute rejection, acute rejection and transplant excellence (stable patients) can be detected as robustly with RNA sequencing as with microarrays. Next-generation sequencing has the potential to offer advantages such as reduced cost of analysis and improved throughput for sample processing. Development of kits enabling assay performance on local lab-based sequencing systems could facilitate expansion of test use worldwide.

About Transplant Genomics Inc.
Transplant Genomics Inc. (TGI) is a molecular diagnostics company committed to improving organ transplant outcomes, with an initial focus on kidney transplant recipients. Working with the transplant community, TGI is commercializing a suite of tests enabling diagnosis and prediction of transplant recipient immune status. Test results will support clinicians with information to optimize immunosuppression therapy, enhance patient care and improve graft survival. Test services are offered through TGI’s CLIA lab in Pleasanton, CA.

Kurian S, Friedewald J, Harrison F, et al. Validation of a blood and biopsy gene expression-based molecular diagnostics for subclinical acute rejection: comparing DNA microarrays vs. next-generation RNA sequencing. Presentation at American Transplant Congress, May 3, 2015.

Source – BusinessWire

One comment

  1. Cell-free DNA based liquid biopsy is the ultimate solution to overcome all limitations of tissue biopsy. However, current version of liquid biopsy requires 10-20 mL of blood due to unavoidable sample loss in cfDNA recovery. Losing a lot of starting materials mean you will compromise the accuracy of the end results in a clinical setting. CirculoGene has come up with a unprecedented finger-stick liquid biopsy enables physicians to work with a sample volume as little as 20 uL!!! It’s crazy the pace that technology advancing.

Leave a Reply

Your email address will not be published. Required fields are marked *


Time limit is exhausted. Please reload CAPTCHA.